REPL — Replimune Group, Inc. stock price, charts and financials

QT88Replimune Group, Inc.

Replimune Group, Inc. (NASDAQ: REPL) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
12.87
-0.09-0.69%
OverviewShort InterestFilings
REPLQT88Replimune Group, Inc.·NASDAQ
12.87-0.69%
Filing
Down 0.7% — Filed an 8-K material-event report (2026-09-16) — details in the filing.
Medium confidence
TA
Loading chart...
Signal & projected range
Analyst consensus risingHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
MESO+3.19%$14.87FTRE+1.55%$20.28NKTR+1.45%$68.36GHRS+3.50%$28.72RAPP+1.35%$41.95AGIO+2.00%$33.61ZBIO-1.08%$31.97GPCR-1.13%$35.10
Snapshot
Index-P/E-EPS (ttm)-Insider Own31.36%Shs Outstand84.03MPerf Week-2.79%
Market Cap1.08BForward P/E-EPS next Y-1.91Insider Trans9.66%Shs Float78.73MPerf Month-17.39%
Enterprise Value994.42MPEG-EPS next Q-0.78Inst Own-Short Float29.87%Perf Quarter28.70%
Income-314.00MP/S0.00EPS this Y-Inst Trans-Short Ratio4.70Perf Half Y90.38%
Sales0.00P/B10.20EPS next Y33.89%ROA-117.65%Short Interest23.52MPerf YTD32.41%
Book/sh1.26P/C5.55EPS next 5Y-ROE-159.32%52W High16.33 -21.19%Perf Year122.28%
Cash/sh2.32P/FCF-EPS past 3/5Y-ROIC-136.14%52W Low1.50 758.00%Perf 3Y-32.90%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility6.21% 5.57%Perf 5Y-59.16%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-8.47%Oper. Margin0.00%ATR (14)0.93Perf 10Y-
Dividend Ex-Date-Quick Ratio5.23Sales Y/Y TTM-Profit Margin0.00%RSI (14)42.21Recom2.33
Dividend Gr. 3/5Y-Current Ratio5.23EPS Q/Q12.20%SMA20-11.53%Beta0.92Target Price18.67
Payout0.00%Debt/Eq0.64Sales Q/Q-SMA502.30%Rel Volume0.29Prev Close12.96
Employees465LT Debt/Eq0.64EarningsNov 05SMA20046.97%Avg Volume4.45MPrice12.87
IPO DateJul 20, 2018Option/ShortYes / YesEPS/Sales Surpr.-3.75% -Net Debt/EBITDA0.25Volume1,293,687Change-0.69%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedBMO CapitalMarket Perform$16 → $20
Aug-07-26UpgradeWedbushNeutral → Outperform$12 → $19
Aug-04-26UpgradeLeerink PartnersMarket Perform → Outperform$34 → $17
Jul-31-26UpgradeCantor FitzgeraldNeutral → Overweight
Jul-31-26ReiteratedWedbushNeutral$9.00 → $12
Jun-30-26ReiteratedBMO CapitalMarket Perform$11 → $16
Jun-30-26ReiteratedWedbushNeutral$18 → $9.00
Jun-26-26UpgradeJP MorganNeutral → Overweight
May-29-26UpgradeJP MorganUnderweight → Neutral
Apr-13-26DowngradeLeerink PartnersOutperform → Market Perform
Latest News· Times ET
Today
Today08:00AM
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harmglobenewswire.com
06:07AM
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallStprnewswire.com
Sep-16-26
Sep-16-2612:11PM
Replimune Says Stockholders Approved Amendment To Increase Authorized Common Shares From 150M To 300M, Effective September 15Benzinga
07:26AM
DEADLINE ALERT for REPL, DVLT, and UWMC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholdersglobenewswire.com
06:07AM
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPLprnewswire.com
12:37AM
Squarepoint Ops LLC Takes Position in Replimune Group, Inc. $REPLdefenseworld.net
Sep-15-26
Sep-15-2602:13PM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPLglobenewswire.com
07:10AM
Portnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. Investorsglobenewswire.com
06:22AM
SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPLglobenewswire.com
06:01AM
Replimune Group, Inc. (REPL) Shareholder/Analyst Call Prepared Remarks Transcriptseekingalpha.com
Sep-14-26
Sep-14-2608:57AM
REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinskyglobenewswire.com
08:00AM
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harmglobenewswire.com
Sep-11-26
Sep-11-2601:48PM
REPL Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against Replimune Group, Inc.globenewswire.com
08:38AM
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Replimune Group Inc. and Encourages Investors to Contact the Firmglobenewswire.com
07:00AM
REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact Levi & Korsinskygurufocus.com
Company

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2026
3/31/2026
FY 2025
3/31/2025
FY 2024
3/31/2024
FY 2023
3/31/2023
FY 2022
3/31/2022
FY 2021
3/31/2021
FY 2020
3/31/2020
FY 2019
3/31/2019
FY 2018
3/31/2018
Total Revenue
000——————
Cost of Goods Sold Incl. D&A
000——————
Gross Profit
000——————
Selling, General and Administrative Excl. Other9900——————
Research and Development221189175——————
Other Operating Expense07360——————
Operating Income-320-262-235——————
Interest Expense987——————
Unusual Expense
—————————
Non-Operating Income (Expense)142326——————
Net Income Before Taxes-314-247-215——————
Income Taxes-100——————
Consolidated Net Income-314-247-216——————
Net Income From Continuing Operations-314-247-216——————
Net Income-314-247-216——————
EPS (Recurring)-3.38-3.07-3.24——————
EPS (Basic, Before Extraordinaries)-3.38-3.07-3.24——————
EPS (Diluted)-3.38-3.07-3.24——————
EBITDA-302-254-228——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding938167——————
Market Capitalization711790547——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$18.12$13.48$8.84$4.20$-0.44● Close Price0.00M0.26M0.52M0.78M1.04MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Hill Emily LuisaChief Financial OfficerAug 17 '26Sale14.289,256132,176215,852Aug 19
Patel SushilChief Executive OfficerAug 10 '26Sale12.9739,341510,253708,151Aug 12
Schwendenman AndrewChief Accounting OfficerAug 10 '26Sale12.977,63298,98799,425Aug 12
Xynos KonstantinosChief Medical OfficerAug 10 '26Sale12.9711,447148,468224,215Aug 12
Hill Emily LuisaChief Financial OfficerAug 10 '26Sale12.9711,448148,481225,108Aug 12
BAKER BROS. ADVISORS LPdirector, 10 percent owner:Aug 11 '26Buy0.002,736,3402742,609,946Aug 11
Sarchi ChristopherChief Commercial OfficerJun 01 '26Sale9.2412,000110,880180,962Jun 03
Patel SushilChief Executive OfficerMay 18 '26Sale5.0837,324189,606747,492May 20
Astley-Sparke PhilipDirectorMay 18 '26Sale5.0817,65789,6981,412,414May 20
Hill Emily LuisaChief Financial OfficerMay 18 '26Sale5.087,81239,685236,556May 20
Schwendenman AndrewChief Accounting OfficerMay 18 '26Sale5.087,89440,102107,057May 20
Xynos KonstantinosChief Medical OfficerMay 18 '26Sale5.0814,02371,237235,662May 20
Sarchi ChristopherChief Commercial OfficerMay 18 '26Sale5.088,62643,820192,962May 20
Sarchi ChristopherChief Commercial OfficerApr 02 '26Sale8.016,50052,065151,588Apr 06
Dhingra KapilDirectorDec 09 '25Option Exercise1.753,1695,5463,169Dec 11
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.